Literature DB >> 17786148

Fatal hepatitis C associated fibrosing cholestatic hepatitis as a complication of cyclophosphamide and corticosteroid treatment of active glomerulonephritis.

Faisal Saleh1, Hin Hin Ko, Jennifer E Davis, Wichian Apiratpracha, James J Powell, Siegfried R Erb, Eric M Yoshida.   

Abstract

Fibrosing cholestatic hepatitis (FCH) is an aggressive and usually fatal form of viral hepatitis in immunocompromised patients. It is characterized by progressive cholestasis leading to hepatic failure, and a characteristic histopathological features including: periportal fibrosis, ballooning degeneration of hepatocytes, cholestasis, with minimal inflammation. FCH has been reported almost exclusively in heavily immunosuppressed organ transplant recipients or patients with AIDS. This case report describes a previously immunocompetent patient with previously stable chronic hepatitis C who developed fibrosing cholestatic hepatitis after receiving cyclophosphamide and corticosteroids for active glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17786148

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  5 in total

1.  Lupus-like glomerulonephritis: an autoimmune complication of hepatitis C infection.

Authors:  Liliane Hobeika; Monica Srivastava; Mai Vo; Marie D Philipneri; David S Brink; Nadia Wasi; Krista L Lentine
Journal:  CEN Case Rep       Date:  2012-03-27

Review 2.  Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.

Authors:  Brian A Baldo; Nghia H Pham
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

3.  Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer.

Authors:  Jaime Ceballos-Viro; José-M López-Picazo; José-L Pérez-Gracia; Jesús-J Sola; Gregorio Aisa; Ignacio Gil-Bazo
Journal:  World J Gastroenterol       Date:  2009-05-14       Impact factor: 5.742

Review 4.  Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road?

Authors:  Chalermrat Bunchorntavakul; Robert Mitrani; K Rajender Reddy
Journal:  J Clin Exp Hepatol       Date:  2017-12-07

5.  Hepatic Failure Due to Cholestatic Hepatitis C in an Immunosuppressed Patient Treated With Elbasvir and Grazeprevir.

Authors:  Amin H Nassar; Baraa M Abdul-Jawad; David S Barnes
Journal:  ACG Case Rep J       Date:  2018-01-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.